Cresco Labs Inc. (CRLBF) EBITDA Margin (2020 - 2026)

Cresco Labs (CRLBF) has reported EBITDA Margin for 7 consecutive years, with 7.71% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 216.0% year-over-year to 7.71%; the trailing twelve-month figure through Jun 2026 stood at 5.1% (down 1611.0% YoY), and the FY2025 full-year result was 4.27%, down 1908.0% from the prior year.
• EBITDA Margin grew to 7.71% in Q2 2026 per CRLBF's latest filing, from 7.38% in the prior quarter.
• Across five years, EBITDA Margin topped out at 23.67% in Q1 2022 and bottomed at 56.55% in Q3 2023.
• Historically, EBITDA Margin has averaged 4.43% across 5 years, with a median of 10.6% in 2025.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 7638 bps in 2023, then soared 7120 bps in 2024.
• Over 5 years, EBITDA Margin stood at 15.3% in 2022, then dropped by 6 bps to 14.4% in 2023, then decreased by 23 bps to 11.03% in 2024, then slumped by 524 bps to 46.76% in 2025, then surged by 116 bps to 7.71% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 7.71%, 7.38%, and 46.76% for Q2 2026, Q1 2026, and Q4 2025 respectively.